Recombinant Human Alpha-Galactosidase A/GLA Protein (His Tag)

Catalog Number: PKSH033249



Note: Centrifuge before opening to ensure complete recovery of vial contents.

-					
	AC	cri	m	Т	٦n
\mathbf{L}		CII		2.	

 Species
 Human

 Mol_Mass
 46.4 kDa

 Accession
 P06280

Bio-activity Not validated for activity

Properties

Purity > 95 % as determined by reducing SDS-PAGE.

Endotoxin $< 1.0 \text{ EU} \text{ per } \mu\text{g}$ of the protein as determined by the LAL method. Storage Storage Storage Storage winimize freeze-thaw cycles.


Shipping This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel

packs. Upon receipt, store it immediately at < - 20°C.

Formulation Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 8.0.

Reconstitution Not Applicable

Data



> 95 % as determined by reducing SDS-PAGE.

Background

α-Galactosidase A is a homodimeric glycoprotein that belongs to the glycosyl hydrolase 27 family. It is a lysosomal enzyme and used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. α-Galactosidase A can hydrolyze terminal α-galactosyl moieties from glycolipids and glycoproteins and catalyze the hydrolysis of melibiose into galactose and glucose. Defects α-Galactosidase A are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease with glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb 3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease.

For Research Use Only